We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The House and Senate conferees met Wednesday to mark up the Comprehensive Addiction and Recovery Act, making a few changes but leaving intact two critical elements related to opioid approval and FDA oversight. Read More
Three clinical investigators were cited for deviating from their investigational plans recently by the FDA for a litany of different reasons. Read More
Pfizer has pledged to communicate all the risks associated with opioids in future ads under an unusual accord it reached with the city of Chicago. Read More
HHS Secretary Sylvia Burwell announced a final rule Tuesday that would more than double the number of patients for whom physicians can prescribe opioid rescue drugs. Read More
The UK’s National Institute for Health and Care Excellence declined to recommend Bristol-Myers Squibb’s Opdivo for reimbursement in the treatment of advanced renal cell carcinoma. Read More